StockSelector.com
  Research, Select, & Monitor Monday, May 27, 2019 7:00:38 AM ET  
Trade Ideas The Market Industries Stocks Portfolio

 
Ticker Lookup
Catalyst Pharmaceuticals, Inc.$3.61$.123.44%

  Quote | Ranking | Chart | Valuations | Sentiment | News | Earnings | Analysts | More...

Your Target?

  Catalyst Pharmaceuticals, Inc. vs Chemicals - Major Diversified

CATALYST PHARMACEUTICAL PARTNERS, INC. is a biopharmaceutical company focused on the development and commercialization of prescription drugs for the treatment of addiction and obsessive compulsive disorders. The Company has obtained from Brookhaven National Laboratory an exclusive worldwide license for Brookhaven's patent portfolio in the US relating to the right to use vigabatrin to treat a wide variety of substance addictions and obsessive compulsive disorders. Catalyst has also been granted rights to Brookhaven's vigabatrin-related foreign patents or patents pending worldwide. The Company's initial product candidate based on vigabatrin is CPP-109. CPP-109 has been granted Fast Track status by the U.S. Food & Drug Administration for the treatment of cocaine addiction. This indicates that the FDA has recognized that CPP-109 is intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrates the potential to address unmet medical needs.




Looking at a few key industries, such as chemical manufacturing, one can usually summarize the strength of a nationís economy. So many industries rely on the raw products of these companies. Fuel additives and detergents are probably the most common encounter we have with products from these firms. They also produce pharmaceuticals, polymers, resins, monomers, plastics, agricultural chemicals, and industrial gases. Just a few of the industries that use these items are aerospace, beverage, electronic, food processing, automotive, and construction.
 Totals Company Industry
  Sales: $0.5 Mil $80,772.4 Mil
  Market Cap: $370.9 Mil $191,162.5 Mil
  Analysts Recommendation: Strong Buy Buy

 Averages Company Industry
 Growth
  Historic Revenue: N/A 16.8%
  Estimated Revenue: 13,712.0% .2%
  Historic Earnings: N/A 25.0%
  Estimated Earnings: N/A 12.2%
  Stock Price (1 Year): 6.2% (19.9%)
  Cash per Share: (71.3%) (7.3%)
  Dividend: N/A N/A
 Price
  Trailing PE: N/A N/A
  Forward PE: 9.5 13.6
  Price-to-Sales: 736.7 N/A
  Price-to-Book: 7.3 2.8
  Dividend Yield: N/A N/A
  Market Cap: $370.9 Mil $23,895.3 Mil
  Operations
  Net Margin: (6,800.0%) 13.6%
  Gross Margin: 100.0% 36.2%
  Return on Equity: (.7) .2
  Return on Assets: (.6) .1
  Balance Sheet
  Current Ratio: 5.8 1.6
  Quick Ratio: 5.8 1.1
  Cash Ratio: 5.6 .3
  Debt-to-Equity: .2 1.7
  Interest Coverage: N/A .6
 Technicals
  Relative-Strength Index: 42.5 N/A

 Other companies in Chemicals - Major Diversified Price Market Cap
  L'Air Liquide ADR  (AIQUY) $25.47 $54,551.6 Mil
  Air Products & Chemicals, Inc.  (APD) $204.49 $45,274.1 Mil
  Henkel KGaA  (HENKY) $21.88 $38,299.2 Mil
  Akzo Nobel N.V.  (AKZOY) $28.42 $19,435.0 Mil
  Celanese Corp  (CE) $99.38 $12,740.5 Mil






Register |  Password |  Feedback |  Copyright |  Usage Agreement |  Privacy Policy |  Advertising |  About Us |  Contact Us |  FAQ 

Past performance is not indicative of future results

StockSelector.com, the StockSelector.com logo, and News Selects are trademarks of StockSelector.com.
Copyright © 1998 - 2019 StockSelector.com. All rights reserved.